Rilmenidine: A clinical overview

American Journal of Hypertension

Volumn 13, Issue 6 II SUPPL., 2000, Pages

  Reid, J L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Efficacy; Essential hypertension; Rilmenidine; Tolerance

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROCHLOROTHIAZIDE; IMIDAZOLINE I2 RECEPTOR; METHYLDOPA; NIFEDIPINE; PLACEBO; RILMENIDINE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROTEINURIA; PROTON SODIUM EXCHANGE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SENESCENCE; SYMPATHETIC TONE; TACHYCARDIA; XEROSTOMIA;

EID: 0033929313     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(00)00226-0     Document Type: Article

References (26)

1. 3H]clonidine. Eur J Pharmacol Mol Pharmacol 1994;266:25-33.
2. Zannad F, Aliot E, Florentin J, Saulnier JP, Gilgenkrantz JM: Hemodynamic and electrophysiologic effects of rilmenidine for systemic hypertension. Am J Cardiol 1988;61:67D-71D.
3. Senechau P, Bousquet P, Dontenwill M: Imidazoline specific binding sites in the human kidney. Arch Pharmacol 1998;358:R747.
4. Kline RL, Cechetto DF: Renal effects of rilmenidine in anesthetized rats: importance of renal nerves. J Pharmacol Exp Ther 1993;266:1556-1562.
5. Kline RL, van der Mark J, Cechetto DF: Natriuretic effect of rilmenidine in anesthetized rats. Am J Cardiol 1994;74:20A-24A.
6. + transport and intracellular pH in renal proximal tubule cells. Biochim Biophys Acta 1990;1024:173-178.
7. 1 imidazoline receptor- selective compounds mediate natriuresis in the rat. J Cardiovasc Pharmacol 1995;26(suppl 2):S63-S67.
8. 1 imidazoline receptor agonist, rilmenidine, in pentobarbital anaesthetized rats. Neurochem Int 1997;30:55-62.
9. Ostermann G, Brisgand B, Schmitt J, Fillastre JP: Efficacy and acceptability of rilmenidine for mild-to-moderate systemic hypertension. Am J Cardiol 1988;61: 76D-80D.
10. Fiorentini C, Guillet C, Guazzi M: Etude multicentrique en double aveugle comparant la rilmenidine 1 mg et l'hydrochlorothiazide 25 mg chez 244 patients. Arch Mal Cœur Vaiss 1989;82(suppl):39-46.
11. Pelemans W, Verhaeghe J, Creytens G, Coupez G, van Dessel A, Opsomer M, Corcoran C: Efficacy and safety of rilmenidine in elderly patients: comparison with hydrochlorothiazide. Am J Cardiol 1994;74:51A-57A.
12. Dallocchio M, Gosse P, Fillastre JP, Grollier G, Morand P, Drici M, Corcoran C: Rilmenidine, a new antihypertensive agent, in the first-line treatment of essential hypertension. A multicentre double-blind study versus atenolol. Presse Med 1991;20:1265-1271.
13. Sadowski Z, Szwed H, Kuch-Wocial A, Kubasik A, Jaruszewicz W, Krupa-Wojciechowska B, Polak G, Steijfa M, Dvorak I, Balazovjech I, Dubai G, Simon K: Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. J Hypertens 1998;16(suppl 3):S55-S62.
14. Dupuy D, Barduceau B, Mayandon M. Am J Hypertens 1999;12:220A.
15. Scemama M, Fevrier B, Beucler I, Dairou F, et le groupe des médecins Euraxi SA: Lipid profile and antihypertensive efficacy in dyslipidemic hypertensive patients: comparison of rilmenidine with captopril. J Cardiovasc Pharmacol 1995;26(suppl 2):S34-S39.
16. Trimarco, B. Am J Hypertens 1999;12:221A.
17. Fillastre JP, Letac B, Galinier F, Le Bihan G, Schwartz J: A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988;61:81D-85D.
18. United Kingdom Working Party on Rilmenidine: Rilmenidine in mild-to-moderate essential hypertension. Curr Ther Res 1990;47:194-211.
19. Galley P, Manciet G, Hessel JL, Michel JP: Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. Am J Cardiol 1988;61:86D-90D.
20. Beau B, Mahieux F, Paraire M, Laurin S, Brisgand B, Vitou P: Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol 1988;61:95D-102D.
21. Luccioni R: Evaluation pharmaco-épidémiologique de la rilménidine chez 18335 hypertendus. Presse Med 1995;24:1857-1864.
22. Velasco M, Soltero I, Sukerman M, et al: Double-blind, randomized study of the efficacy, tolerance, and rebound effects of the antihypertensive drug rilmenidine: comparative evaluation with clonidine. Curr Ther Res 1993;54:202-207.
23. Panfilov V, Morris A, Donnelly R, Reid JL: Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. J Cardiovasc Pharmacol 1995;26(suppl 2):S44-S47.
24. Mpoy M, Vandeleene B, Ketelslegers JM, Lambert AE: Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol 1988; 61:91D-94D.
25. Lubetzki J: Etude chez l'hypertendu diabétique non insulino-dépendant de l'activité antihypertensive et de l'acceptabilité de la rilménidine (S 3341). Essai réalisé chez 16 patients traités pendant trois mois aux posologies journalières de 1 et 2 mg. Expert study. 1986.
26. Trimarco B, Rosiello G, Sarno D, Argenziano L, Rubattu S, de Luca N, Volpe M: Rilmenidine in patients with left ventricular hypertrophy due to essential hypertension: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol. 1995;26(suppl 2):S29-S33.